CNChristopher G. Nasveschuk

Christopher G. Nasveschuk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher G. Nasveschuk has a total of 146 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9

    by Katrina L. Jackson, Ning Yin, Roman V. Agafonov, Prasoon Chaturvedi, Kyle Cole, Scott J. Eron, Andrew C. Good, June A. Hart, Minsheng He, Christina S. Henderson, et al.

    The chromatin factor bromodomain-containing protein 9 (BRD9) is a genetic dependency in SMARCB1-perturbed or SMARCB1-null cancers including synovial sarcoma. In such cancers, the degradation of BRD9 is hypothesized to result in an anticancer effect. Here, we report the discovery and characterization of CFT8634, an orally bioavailable heterobifunctional degrader that mediates potent and selective proteasomal degradation of BRD9. Oral dosing of CFT8634 in preclinical mouse xenograft models led to dose-dependent BRD9 degradation and tumor growth inhibition. Based on its promising preclinical profile, CFT8634 was advanced into a Phase 1 study in patients with SMARCB1-perturbed and -null tumors. CFT8634 demonstrated dose-dependent increases in human exposure with robust pharmacodynamic response but only modest efficacy outcomes in late-line patients. Further, the advancement of CFT8634 as a monotherapy was inhibited by the emergence of cardiac toxicities. Nevertheless, this first study of an orally bioavailable BRD9 degrader recapitulates preclinical pharmacokinetic and pharmacodynamic observations in a clinical trial setting.


  • CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance

    by Bridget T. Kreger, Yanke Liang, Nicole M. Reilly, Meghan E. Spears, William A. Scott, Jeffrey R. Simard, Ping Li, Prasoon Chaturvedi, Roman V. Agafonov, Jacob Stephenson, et al.

    Currently approved BRAF inhibitors (BRAFi) have achieved impressive efficacy in BRAFV600-mutant cancers. However, the clinical benefit of BRAFis is limited by several factors, including vulnerability to RAF dimer–driven resistance mechanisms, poor brain penetration, and side effects arising from paradoxical activation of MAPK signaling in normal tissue. In this study, we aimed to overcome these limitations by developing CFT1946, a potent, orally bioavailable, and brain-penetrant cereblon-based bifunctional degrader that targets BRAFV600-mutant protein while sparing wild-type RAF family members. CFT1946 demonstrated potent activity in preclinical models of BRAFV600-mutant driven melanoma and colorectal cancer while sparing wild-type MAPK signaling and mitigating the paradoxical activation associated with approved BRAFis. CFT1946 was efficacious in an intracranial BRAFV600E melanoma tumor model and demonstrated robust activity in multiple cellular and patient-derived BRAFV600-mutant melanoma and colorectal cancer models of acquired and adaptive RAF dimer–driven BRAFi resistance. CFT1946 therefore represents an effective therapeutic modality with the potential to overcome the key limitations of current BRAFV600-mutant targeted therapies. Significance: CFT1946 is a clinical stage, orally available, brain-penetrant BRAFV600-mutant protein degrader that overcomes RAF dimer–driven resistance mechanisms to currently approved BRAF inhibitors and represents a promising approach to treating BRAFV600-mutant tumors. See related commentary by Chen and Bollag, p. 289


  • Open Access

    Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex

    by Qi Hao, Manoj K. Rathinaswamy, Kelly L. Klinge, Matthew Bratkowski, Amirhossein Mafi, Christina K. Baumgartner, Keith M. Hamel, Gesine K. Veits, Rinku Jain, Claudio Catalano, et al.

    PTPN2 (protein tyrosine phosphatase non-receptor type 2, or TC-PTP) and PTPN1 are attractive immuno-oncology targets, with the deletion of Ptpn1 and Ptpn2 improving response to immunotherapy in disease models. Targeted protein degradation has emerged as a promising approach to drug challenging targets including phosphatases. We developed potent PTPN2/N1 dual heterobifunctional degraders (Cmpd-1 and Cmpd-2) which facilitate efficient complex assembly with E3 ubiquitin ligase CRL4CRBN, and mediate potent PTPN2/N1 degradation in cells and mice. To provide mechanistic insights into the cooperative complex formation introduced by degraders, we employed a combination of structural approaches. Our crystal structure reveals how PTPN2 is recognized by the tri-substituted thiophene moiety of the degrader. We further determined a high-resolution structure of DDB1-CRBN/Cmpd-1/PTPN2 using single-particle cryo-electron microscopy (cryo-EM). This structure reveals that the degrader induces proximity between CRBN and PTPN2, albeit the large conformational heterogeneity of this ternary complex. The molecular dynamic (MD)-simulations constructed based on the cryo-EM structure exhibited a large rigid body movement of PTPN2 and illustrated the dynamic interactions between PTPN2 and CRBN. Together, our study demonstrates the development of PTPN2/N1 heterobifunctional degraders with potential applications in cancer immunotherapy. Furthermore, the developed structural workflow could help to understand the dynamic nature of degrader-induced cooperative ternary complexes.


  • Open Access

    Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, and a deficiency of reliable biomarkers may contribute to the lack of efficacy in solid tumors. In this article, we report the discovery and preclinical development of the novel, orally bioavailable, class-I–selective HDAC inhibitor, OKI-179. OKI-179 and its cell active predecessor OKI-005 are thioester prodrugs of the active metabolite OKI-006, a unique congener of the natural product HDAC inhibitor largazole. OKI-006, OKI-005, and subsequently OKI-179, were developed through a lead candidate optimization program designed to enhance physiochemical properties without eroding potency and selectivity relative to largazole. OKI-005 displays antiproliferative activity in vitro with induction of apoptosis and increased histone acetylation, consistent with target engagement. OKI-179 showed antitumor activity in preclinical cancer models with a favorable pharmacokinetic profile and on-target pharmacodynamic effects. Based on its potency, desirable class I HDAC inhibition profile, oral bioavailability, and efficacy against a broad range of solid tumors, OKI-179 is currently being evaluated in a first-in-human phase I clinical trial with plans for continued clinical development in solid tumor and hematologic malignancies.

  • Open Access

    Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • Open Access

    Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • Open Access

    Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • Open Access

    Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

  • Open Access

    Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors

    by Jennifer R. Diamond, Todd M. Pitts, Dana Ungermannova, Christopher G. Nasveschuk, Gan Zhang, Andrew J. Phillips, Stacey M. Bagby, Jessica Pafford, Betelehem W. Yacob, Timothy P. Newton, et al.

    Histone deacetylases (HDACs) play critical roles in epigenomic regulation, and histone acetylation is dysregulated in many human cancers. Although HDAC inhibitors are active in T-cell lymphomas, poor isoform selectivity, narrow therapeutic indices, and a deficiency of reliable biomarkers may contribute to the lack of efficacy in solid tumors. In this article, we report the discovery and preclinical development of the novel, orally bioavailable, class-I–selective HDAC inhibitor, OKI-179. OKI-179 and its cell active predecessor OKI-005 are thioester prodrugs of the active metabolite OKI-006, a unique congener of the natural product HDAC inhibitor largazole. OKI-006, OKI-005, and subsequently OKI-179, were developed through a lead candidate optimization program designed to enhance physiochemical properties without eroding potency and selectivity relative to largazole. OKI-005 displays antiproliferative activity in vitro with induction of apoptosis and increased histone acetylation, consistent with target engagement. OKI-179 showed antitumor activity in preclinical cancer models with a favorable pharmacokinetic profile and on-target pharmacodynamic effects. Based on its potency, desirable class I HDAC inhibition profile, oral bioavailability, and efficacy against a broad range of solid tumors, OKI-179 is currently being evaluated in a first-in-human phase I clinical trial with plans for continued clinical development in solid tumor and hematologic malignancies.

  • GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1

    by Alexander M. Taylor, Chris Bailey, Lisa D. Belmont, Robert Campbell, Nico Cantone, Alexandre Côté, Terry D. Crawford, Richard Cummings, Kevin DeMent, Martin Duplessis, et al.

    Bromodomains are acetyllysine recognition domains present in a variety of human proteins. Bromodomains also bind small molecules that compete with acetyllysine, and therefore bromodomains have been targets for drug discovery efforts. Highly potent and selective ligands with good cellular permeability have been proposed as chemical probes for use in exploring the functions of many of the bromodomain proteins. We report here the discovery of a class of such inhibitors targeting the family VIII bromodomains of SMARCA2 (BRM) and SMARCA4 (BRG1), and PBRM1 (polybromo-1) bromodomain 5. We propose one example from this series, GNE-064, as a chemical probe for the bromodomains SMARCA2, SMARCA4, and PBRM1(5) with the potential for in vivo use.